Skip to main content

Table 1 Selected real world clinical studies of Saroglitazar

From: New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Group Study duration Number of studies Selected studies
Group 1 12 weeks 4 Shetty et al. [13], Thacker et al. [14], Joshi et al. [15], Bhattacharyya et al. [16]
Group 2 24 weeks 6 Saboo et al. [17], Joshi et al. [18], Chhaya et al. [19], Mohit et al. [20], Kaul et al. [21], Goyal et al. [22]
Group 3 27 weeks 1 Chatterjee et al. [23]
Group 4 36 weeks 1 Joshi et al. [24]
Group 5 40 weeks 1 Chatterjee et al. [25]
Group 6 52 weeks 4 Joshi et al. [26], Aneja et al. [27], Maheshwari et al. [28], Chatterjee et al. [29]
Group 7 58 weeks 1 Chatterjee et al. [30]